CLINICAL EFFICACY OF COMBINED NEUROPROTECTION IN PATIENTS WITH COVID-19 DISEASE
Аннотация
This article discusses the clinical efficacy of combined
neuroprotection in patients with COVID-19 disease. When detailing the results
of testing on the MoCA scale, in general, the examined patients were dominated
by changes in the executive function of drawing a broken line, optical-spatial
disorders, and worsening of delayed word reproduction (hearing-speech
memory). At the same time, auditory-verbal memory disorders were more often
observed in patients with MG.
Библиографические ссылки
Baer, M. Neuroprotection: models, mechanisms, therapy / M. Baer. -
Moscow: BINOM. knowledge laboratory,2011. – P. 429.
Domashenko M.A., Maksimova M.Yu., Sergeev D.V., Piradov M.A. Citicoline
in the treatment of ischemic disorders of cerebral circulation // BC. 2013. № 30.
P. 1540–1542.
Lomonosov, O.V. Cerebral strokes: rehabilitation of patients and disabled
people of working age in the metropolis: Abstract of the thesis. cand. honey.
Sciences. / Lomonosova O.V. - St. Petersburg, 2021. – P. 24.
Sergeev D.V., Piradov M.A. Citicoline in the treatment of ischemic stroke -
new evidence of effectiveness // BC. 2012. № 31. P.1552–1554.
